Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics reports developments as a commercial-stage biopharmaceutical company focused on therapies for rare diseases. Recurring updates center on MIPLYFFA (arimoclomol), its U.S.-approved treatment for Niemann-Pick disease type C, including commercialization, patient access, regulatory activity and diagnostic-support initiatives tied to NPC.
Zevra news also covers financial results, pipeline programs in rare diseases such as vascular Ehlers-Danlos syndrome, and corporate actions that shape its portfolio. Recent company updates include the completed sale of the serdexmethylphenidate, or SDX, portfolio, including AZSTARYS and KP1077, as well as governance and executive-compensation announcements under Nasdaq rules.
Zevra (NasdaqGS: ZVRA) reported Q1 2026 results on May 6, 2026. Net revenue was $36.2 million, up 78% year-over-year, including $24.6 million from MIPLYFFA. The company completed a $50.0 million sale of its SDX portfolio and prepaid a $63.1 million term loan, leaving cash of $236.8 million.
Pipeline updates include Phase 3 DiSCOVER enrollment progress (62 patients, two events) and an EMA review of arimoclomol for NPC; a conference call was held May 6, 2026.
Zevra Therapeutics (NasdaqGS: ZVRA) will report first-quarter 2026 corporate and financial results on Wednesday, May 6, 2026 via a news release after the market close and host a conference call/audio webcast at 4:30 p.m. ET.
A link and replay (available for 90 days beginning ~5:30 p.m. ET) will be on the Events & Presentations page at investors.zevra.com. Telephone dial-in and Conference ID ZVRAQ126 are provided for participants.
Zevra Therapeutics (Nasdaq: ZVRA) granted an inducement equity award to new CFO Justin Renz effective March 18, 2026 under its 2023 Employment Inducement Award Plan.
The company approved a new-hire option for 300,000 shares with a 10-year term, exercise price of $9.55 (closing price on March 18, 2026), and four-year vesting subject to continued service. The award was approved under Nasdaq Rule 5635(c)(4).
Zevra Therapeutics (NasdaqGS: ZVRA) agreed to sell its entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million on March 16, 2026.
As part of the transaction the parties mutually settled prior Delaware litigation, and Zevra repaid the principal on its $63 million term loan, leaving a debt-free balance sheet.
GeneDx (Nasdaq: WGS) and Zevra Therapeutics announced a Sponsored Genetic Testing Program to expand access to GeneDx’s ExomeDx test for U.S. patients with suspected Niemann-Pick disease type C (NPC). Eligible patients may receive testing at no charge, with results available in as little as three weeks.
De-identified data from the program will be added to GeneDx Infinity™, aiming to improve NPC diagnosis speed and support clinical decision-making as new therapies emerge. Zevra will provide financial support for the program.
Zevra (NASDAQ: ZVRA) reported Q4 revenue of $34.1M (Q4 growth 31% QoQ) and FY2025 net revenue of $106.5M, driven by MIPLYFFA net revenue $87.4M. FY2025 net income was $83.2M ($1.40 basic, $1.35 diluted). Cash and securities totaled $238.9M at year-end.
Regulatory progress: EMA MAA under review; U.S. EAP enrolled 113 patients; Phase 3 DiSCOVER enrollment ongoing (52 patients).
Zevra Therapeutics (Nasdaq: ZVRA) appointed Justin Renz as Chief Financial Officer, effective March 9, 2026. Renz brings more than 25 years of biopharmaceutical financial leadership, experience in capital markets and commercial launches, and holds CPA credentials and multiple advanced degrees.
This leadership change positions Zevra to strengthen its financial foundation as it advances commercialization and execution of its rare disease strategy.
Zevra Therapeutics (Nasdaq: ZVRA) will report fourth quarter and full year 2025 corporate and financial results on Monday, March 9, 2026 after market close, followed by a conference call and audio webcast at 4:30 p.m. ET. The live webcast link and replay will be available on the company’s Investor Relations Events & Presentations page.
Telephone dial-ins include a U.S. number and an international number; a replay will be available for 90 days beginning about 5:30 p.m. ET.
Zevra Therapeutics (Nasdaq: ZVRA) announced that its executive leadership will present at the Citizens Life Sciences Conference in Miami Beach on March 11, 2026 at 9:00 a.m. ET.
Management will hold one-on-one meetings with registered attendees and a live webcast will be available via the Events & Presentations page on Zevra's investor website.
Zevra Therapeutics (NasdaqGS: ZVRA) presented four posters at the 22nd Annual WORLDSymposium on MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C (NPC).
Key highlights: four-year U.S. Early Access Program (EAP) data showing tolerability and disease stabilization across pediatric and adult patients, a post hoc NPC002 analysis showing statistically significant slowing versus placebo from month 3 through 12, and the first multi-year adult NPC dataset.